3D printing technology will eventually eliminate the need of purchasing commercial phantoms for clinical medical physics QA procedures 1 | INTRODUCTION 3D printing is not a new concept. The recent advances in printing speed, technology, and material selection are promoting its significant impacts in several industries, including health care. For our medical physics field, researchers are also finding its applications in various clinical aspects. However, the interests still remain in a few academic centers who have the luxuries of owning such an unconventional device in the radiation oncology department, or collaborating with a local 3D printing lab. As the 3D printing technology is becoming an unstoppable driving force in manufacturing revolution, are we also envisioning a future that 3D printing will become as common as a block-cutting machine in a radiation oncology department? In this debate, we invited two researchers who are experienced in studying the clinical use of 3D printing in medical physics field. Dr. Eric Ehler is arguing for the proposition that "3D printing technology will eventually eliminate the need of purchasing commercial phantoms for clinical medi-
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Phantoms provide medical physicists a means to assess the performance of medical devices in imaging, nuclear medicine, and radiation therapy. 1 Historically, phantoms were designed and constructed by clinical staff and/or hospital engineers using materials and formulations available to them at the time. 2 Currently, many vendors in the medical physics market provide a wide array of phantoms for clinical use. The reason for this shift could reasonably be attributed to convenience and in the interest of standardization of quality check (QC)
procedures and quality assurance (QA) programs.
3D printing has been around since 1980s. 3, 4 The expiration of patents related to 3D printing has lowered the cost of 3D printers.
3D printing technology has been described as the democratization of manufacturing; 3D printing is shifting the means of manufacture from a centralized system to a distributed network. The impact of increased access to manufacturing capability will reduce the convenience factor of commercial phantoms as clinicians can custom design and print phantoms as needed.
The argument "3D printing technology will eventually eliminate the need of purchasing commercial phantoms for clinical medical physics QA procedures" is already becoming reality. In most clinics, the Linac morning QA is performed with a commercial image guidance radiotherapy (IGRT) phantom, which is a cubic phantom with marks on the faces for laser alignment and embedded features for x-ray imaging. An IGRT phantom with submillimeter accuracy was fabricated and reported by Woods et al. 5 using computer-aided design freeware and a relatively low cost 3D printer (commercially available for $3150 USD). In our clinic, rather than purchasing multiple identical IGRT phantoms, our team designed our own phantom in a similar manner as Woods et al. The phantom was 3D printed with PET-G plastic for a cost of $10, using a 3D printer in a cost range of $900. The 3D printed phantom did not have the full capabilities of our commercial IGRT phantom but it fits our clinical needs as we did not fully use the features of the commercial phantom during morning QA. Additionally, when compared to a commercial small animal PET/CT imaging phantom, the 3D printed phantom was described as "functionally equivalent to commercially available phantoms". 6 3D printed phantoms have also been described for MRI 7 and PET/MRI 6 systems. A feature of these phantoms is that they can be customized and produced by the end users at a low cost. 
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3D printing is a transformative technology that allows users to physically manufacture anything that they can model with a computer.
Over the last several years there has been enthusiastic and rapid adoption of 3D printing technology in medical physics to create a wide spectrum of custom, patient-specific devices. 3D printers are well-suited to manufacture a number of devices that are currently much more expensive, or much more inconvenient to procure from commercial vendors. These include customized, patient-specific bolus and customized phantoms that may only be used once, or for a single patient. However, despite the interesting applications and enormous potential of 3D printing technology for some radiotherapy applications, presently, there are several limitations that will prevent it from being uniformly adopted as the preferred phantom fabrication technique in hospitals across the country.
The first major limitation of 3D printing is the material properties of 3D printed parts. 3D printable materials must have some specific properties; they have to either be a thermoplastic with a glass transi- 8, 19 or use custom inhouse mixed materials to mimic bone that requires custom filament creating equipment. 20 The first solution reduces the usefulness of the phantom, and the second solution dramatically reduces the convenience that 3D printing was supposed to provide in the first place.
Similarly, the lungs are usually left open, or printed with "low infill" that matches lung density but is highly variable depending on the direction of an incident radiation beam. 21, 22 Contrast this 3D printed phantom with a common commercial anthropomorphic phantom which comes with several different tissue types, including bone, cartilage, brain, soft tissue, and lung (Computerized Imaging Reference Systems, Inc. A Castleray company, Norfolk, VA). Additionally, these phantoms' low density material properties do not depend on the direction of incident radiation like low density 3D printed phantoms.
Even if a full range of perfectly matched 3D printable materials were to be found, there are still large variations between identical 3D printed parts. We have previously shown that identically printed blocks of material can vary in density from each other up to 7%, 23 and that is using the same printer, the same model, and the same roll of filament. There are currently dozens of different kinds of 3D printers in use in clinics around the country using many different materials and printer settings. If 3D printing QA devices becomes commonplace, it will be difficult to make meaningful comparisons of measurements across institutions that are using different 3D printers to produce phantoms based on their own specific materials and printing protocols.
Another problem with wide adoption of 3D printing is increased cost and complexity. To be clear, the actual material costs to 3D print a simple phantom are almost certainly less than the cost to purchase a similar commercial phantom. remember that in-house phantom production will require in-house 3D printing expertise, so will it be the medical physicist's responsibility to be proficient in 3D design as well as the mechanical operation and maintenance of a 3D printer? Whose responsibility will it be if the 3D printer jams during a print and patient QA cannot be performed? 3D printers mostly operate in the background, but they do require operators to plan and start models printing, as well as change out materials and occasionally replace parts. Especially with less expensive printers the user must be able to troubleshoot and fix errors. This may be feasible in larger academic centers, but I do not think it is a reasonable expectation that the many small or nonacademic clinics that make up the majority of cancer care will embrace this unnecessary increased workload.
In conclusion, 3D printing is currently not a mature enough tech- It is true that currently available 3D printing materials are not equivalent to human tissues. Attributable to the complexity in designing a material that is compatible with 3D printing and is tissue or water equivalent, materials science developments are needed. In the meantime, there is an alternative to fully 3D printing a phantom if it is desired to be tissue or water equivalent. That is to use 3D printing to create a mold to fill with an equivalent material(s); this strategy can be used for phantoms 9 as well as radiotherapy bolus. Finally, I contest the statement that 3D printing may be feasible for large academic centers but not for smaller clinics. In fact, I
believe that the greatest benefit will be to smaller clinics. At a large academic center, there are likely engineers within the hospital and engineering machine shops nearby to fabricate phantoms and devices. Smaller clinics likely lack these resources and 3D printing can fill that gap at a reasonable cost.
3.B | Daniel Craft, PhD
There are several points upon which Dr. Ehler and I agree. First, and most importantly, we share a concern for some of the variable material properties that 3D printed objects can have. As he notes, different material suppliers are not held to strict material standards, which can lead to various imperfections and inconsistencies in 3D printed parts.
Objects printed from different suppliers using an equivalently labeled material could have different densities and radiological properties. 23, 24 This is, however, not the only potential source of uncertainty. I would add that the quality of a printed object will depend equally as largely on the 3D printer used, and the model that has been designed. There are many 3D printers with slightly different properties that could affect print quality, such as how stable it can maintain the nozzle and bed temperature, how fast the extruder moves, and many more. Additionally, unless 3D models of useful phantoms are shared across all institutions there will be additional variation between clinics in the actual characteristics of phantoms used for QA.
This leads to the second point on which we have common ground: if phantoms are printed in house, calibration and standardization tests into dimensional accuracy, material uniformity, and material attenuation properties will also have to be performed in house. As Dr. Ehler notes, these certifications currently come with phantoms from commercial suppliers. While larger research institutions may have additional resources and time to make this in house testing feasible, having to perform these tests for every printed object is an unnecessary workload for most smaller clinics. This increased workload for physicists in designing objects to be printed, maintaining a 3D printer, and validating 3D printed objects is in my opinion a major limiting factor in the widespread adoption of clinical 3D printing.
As Dr. Ehler has mentioned, another use for 3D printing aside from creating clinical phantoms is the creation of patient-specific treatment devices. This is a very interesting application of 3D printing, because many of these devices are currently difficult, time-consuming, or expensive to acquire through conventional fabrication.
With 3D printing, however, patient specific bolus 13, 15, 25 can be rapidly and inexpensively produced that reduces air gaps and improves dosimetric plan characteristics relative to less conformal bolus. In fact, I agree with Dr. Ehler that "the strongest argument for clinical acquisition of 3D printing technology is for the fabrication of treatment devices." I disagree, however, with his assertion that this technology can be applied equally to creating phantoms for every clinical need. Although 3D printed bolus is in many ways more convenient than and superior to conventional bolus, 3D printed phantoms are generally harder to manufacture and have inferior material properties relative to conventional phantoms.
Ultimately, the debate around 3D printing taking over conventional commercial phantoms is an argument of magnitude. It is clear that 3D printing is currently being used in clinics around the country for a variety of interesting purposes including phantom development, 9,11 treatment device fabrication, 13, 16 and more. 7, 26, 27 As the technology matures and continues to develop I am sure that it will improve and more use cases will be found. However, it is my opinion that 3D printing will remain a supplemental technology to fabricate a few special things, and will not ever completely replace conventionally fabricated commercial phantoms.
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